Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
161 studies found for:    IL2RA
Show Display Options
Rank Status Study
1 Active, not recruiting Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Condition: End Stage Renal Disease
Interventions: Drug: Rabbit Antithymocyte globulin;   Drug: Daclizumab
2 Completed A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Daclizumab
3 Completed Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Condition: Renal Transplantation
4 Recruiting Preemptive Therapy of GVHD
Condition: Graft-vs-host Disease
Intervention: Drug: rabbit antithymocyte globulin
5 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
6 Unknown  Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
Conditions: Kidney Transplantation;   Kidney Diseases;   Kidney Failure
Interventions: Drug: Alemtuzumab;   Drug: Daclizumab
7 Unknown  A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Interventions: Drug: Daclizumab;   Drug: Daclizumab (Zenapax)
8 Completed
Has Results
Abatacept With Methotrexate- Phase IIB
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept (BMS-188667);   Drug: Placebo
9 Completed
Has Results
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Methotrexate;   Drug: Placebo
10 Completed
Has Results
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo
11 Completed
Has Results
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Conditions: Graft vs Host Disease;   Myelodysplastic Syndromes;   Leukemia;   Leukemia, Myeloid;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Lymphocytic;   Lymphoma;   Lymphoma, Mantle-cell;   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: RFT5-SMPT-dgA;   Drug: Nexell Isolex system
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
13 Completed
Has Results
Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)
Condition: Renal Transplantation
Interventions: Drug: Simulect®;   Drug: Neoral®;   Drug: Certican®;   Drug: Myfortic®;   Drug: Corticosteroids
14 Withdrawn Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
Interventions: Biological: IL-2 secreting and hCL4OL-expressing autologous B-CLL cells;   Biological: IL-2;   Biological: CD40L;   Drug: ONTAK;   Biological: immunotoxin dose
15 Completed Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Conditions: Ulcerative Colitis;   Gastrointestinal Disease;   Inflammatory Bowel Disease
Intervention: Drug: Daclizumab
16 Recruiting Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay
Condition: Renal Transplant Recipients
Intervention: Other: Cylex ImmuKnow Assay
17 Unknown  Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
18 Enrolling by invitation Clinical Study of the Pharmacogenetic / Pharmacokinetic / Pharmacodynamic Relationships of Calcineurin Inhibitors Cyclosporine and Tacrolimus in Liver Transplant Recipients
Conditions: Liver Transplantation;   Graft Versus Host Disease;   Infection;   Cardiovascular Diseases;   Malignancy
19 Active, not recruiting Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
Condition: Kidney Transplantation
Interventions: Drug: Advagraf;   Biological: Simulect;   Drug: Cellcept;   Drug: Corticosteroids;   Drug: Ramipril;   Drug: Irbesartan
20 Completed
Has Results
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Condition: Renal Transplantation
Interventions: Drug: Everolimus (RAD001);   Drug: Tacrolimus;   Drug: Basiliximab;   Drug: Corticosteroids

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years